Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03520647 · ClinicalTrials.gov registry record · Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

A Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Severe Aplastic Anemia (SAA), sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Recruiting
Registry status
Phase 2
Development phase
56
Enrollment target
1
Study location

NCT03520647 is a Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Severe Aplastic Anemia (SAA) that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 56 participants, below the 115-participant average among 5 other Paroxysmal Nocturnal Hemoglobinuria (PNH) trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03520647, a Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Severe Aplastic Anemia (SAA), is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

RECRUITING
Registry status
Phase 2
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

Background: Severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) cause serious blood problems. Stem cell transplants using bone marrow or blood plus chemotherapy can help. Researchers want to see if using peripheral blood stem cells (PBSCs) rather than bone marrow cells works too. PBSCs are easier to collect and have more cells that help transplants. Objectives: To see how safely and effectively SAA, MDS and PNH are treated using peripheral blood hematopoietic stem cells from a family member plus chemotherapy. Eligibility: Recipients ages 4-60 with SAA, MDS or PNH and their relative donors ages 4-75 Design: Recipients will have: * Blood, urine, heart, and lung tests * Scans * Bone marrow sample Recipients will need a caregiver for several months. They may make fertility plans and a power of attorney. Donors will have blood and tissue tests, then injections to boost stem cells for 5-7 days. Donors will have blood collected from a tube in an arm or leg vein. A machine will separate stem cells and maybe white blood cells. The rest of the blood will be returned into the other arm or leg. In the hospital for about 1 month, recipients will have: * Central line inserted in the neck or chest * Medicines for side effects * Chemotherapy over 8 days and radiation 1 time * Stem cell transplant over 4 hours Up to 6 months after transplant, recipients will stay near NIH for weekly physical exams and blood tests. At day 180, recipients will go home. They will have tests at their doctor s office and NIH several times over 5 years.

Conditions Studied

Paroxysmal Nocturnal Hemoglobinuria (PNH) Severe Aplastic Anemia (SAA) Hypo-Plastic Myelodysplastic Syndrome (MDS)

Interventions

  • DRUG Cyclophosphamide
  • OTHER Peripheral Blood Stem Cells

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2019-02-19
Est. Completion 2028-06-01
Phase Phase 2

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

501 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03520647

The ClinicalTrials.gov registry entry for NCT03520647 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 5 other Paroxysmal Nocturnal Hemoglobinuria (PNH) trials with a reported enrollment target (51% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Paroxysmal Nocturnal Hemoglobinuria (PNH) appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.

NCT03520647 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03520647 about?

NCT03520647 is a clinical study titled "Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis". Background: Severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) cause serious blood problems. Stem cell transplants using bone marrow or blood plus chemotherapy can help. Researchers want to see if using peripheral blood stem cells (PBSCs...

What is the current status of trial NCT03520647?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2019-02-19. Estimated completion is 2028-06-01.

What conditions does trial NCT03520647 study?

This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS).

What interventions are being tested in trial NCT03520647?

The interventions under investigation include: Cyclophosphamide (DRUG), Peripheral Blood Stem Cells (OTHER).

Who is sponsoring clinical trial NCT03520647?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03520647 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Paroxysmal Nocturnal Hemoglobinuria (PNH)

All registered trials for this condition

Severe Aplastic Anemia (SAA)

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.